RUA Life Sciences plc
RUA.L · LSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | £7,500 | £2,937 | £11,425 | £10,871 |
| - Cash | £3,567 | £3,931 | £1,484 | £2,963 |
| + Debt | £1,029 | £389 | £475 | £344 |
| Enterprise Value | £4,962 | -£605 | £10,416 | £8,252 |
| Revenue | £4,113 | £2,191 | £2,179 | £1,625 |
| % Growth | 87.7% | 0.6% | 34.1% | – |
| Gross Profit | £3,172 | £1,716 | £1,433 | £1,045 |
| % Margin | 77.1% | 78.3% | 65.8% | 64.3% |
| EBITDA | £401 | -£1,573 | -£1,948 | -£2,039 |
| % Margin | 9.7% | -71.8% | -89.4% | -125.5% |
| Net Income | £1 | -£1,440 | -£2,003 | -£2,067 |
| % Margin | 0% | -65.7% | -91.9% | -127.2% |
| EPS Diluted | 0 | -0.043 | -0.09 | -0.093 |
| % Growth | 100% | 52.5% | 3.1% | – |
| Operating Cash Flow | -£219 | -£1,328 | -£1,174 | -£2,361 |
| Capital Expenditures | -£62 | -£55 | -£449 | -£904 |
| Free Cash Flow | -£281 | -£1,383 | -£1,623 | -£3,265 |